Necesidad del razonamiento clínico en la era de la medicina basada en la evidencia

1. Sackett DJ, Rosenberg WM, Gray JA, Haynes RB, Richardson WS. Evidence based medicine: what it is and what it isn’t. BMJ. 1996; 312(7023):71-72.
2. Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989; 321(6):406-412.
3. Howick JH. The Philosophy of Evidence-Based Medicine. Chichester, United Kingdom: Wiley-Blackwell/BMJ Books; 2011.
4. Tricoci P, Allen JM, Dramer JM, Califf RM, Smith SC Jr. Scientific evidence underlying the ACC/AHA clinical practice guidelines. JAMA. 2009; 301(8):831-841.
5. Wilson W, Taubert KA, Gewitz M, et al. Prevention of infective endocarditis: guidelines from the American Heart Association: a guideline from the American Heart Association Rheumatic Fever, Endocarditis, and Kawasaki Disease Committee, Council on Cardiovascular Disease in the Young, and the Council on Clinical
Cardiology, Council on Cardiovascular Surgery and Anesthesia, and the Quality of Care and Outcomes Research Interdisciplinary Working Group. Circulation. 2007; 116(15): 1736-1754.
6. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA. 1997; 277(22):1794-1801.
7. Ioannidis JP. Contradicted and initially stronger effects in highly cited clinical research. JAMA. 2005;294(2):218-228.
8. Pereira TV, Ioannidis JP. Statistically significant meta-analyses of clinical trials have modest credibility and inflated effects. J Clin Epidemiol. 2011; 64(10):1060-1069.
9. Should healthy people take cholesterol drugs to prevent heart disease? Wall Street Journal. http://online.wsj.com/article/SB10001424052970203471004577145053566185694.htmlAccessed January 11, 2013.
10. Sniderman A, Thanassoulis G, Couture P, Williams K, Alam A, Furberg CD. Is lower and lower better and better? a reevaluation of the evidence from the Cholesterol Treatment Trialists’ Collaboration meta-analysis for low-density lipoprotein lowering. J Clin Lipidol. 2012; 6(4):303-309.
11. Catapano AL, Reiner Z, De Backer G, et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis. 2011; 217(1):3-46.
12. Anderson TJ, Grégoire J, Hegele RA, et al. 2012 Update of the Canadian Cardiovascular Society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult. Can J Cardiol. 2013; 29(2):151-167.
13. US Food and Drug Administration website. FDA Drug Safety Communication: New restrictions, contraindications, and dose limitations for Zocor (simvastatin) to reduce the risk of muscle injury. http://www.fda.gov/Drugs/DrugSafety/ucm256581.htm. Accessed April 1, 2013
14. Joy TR, Hegele RA. Narrative review: statin-related myopathy. Ann Intern Med. 2009; 150(12):858-868.
15. Preiss D, Seshasai SR, Welsh P, et al. Risk of incident diabetes with intensive-dose compared with moderate dose statin therapy: a meta-analysis. JAMA. 2011; 305(24): 2556-2564.
16. Dormuth CR, Hemmelgarn BR, Paterson JM, et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ. 2013; 346(4):f880.
17. Diao D, Wright JM, Cundiff DK, Gueyffier F. Pharmacotherapy for mild hypertension. Cochrane Database Syst Rev. 2012;(8): CD006742.
18. Chobanian AV, Bakris GL, Black HR, et al; National Heart, Lung, and Blood Institute Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure; National High Blood Pressure Education Program Coordinating Committee. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure: the JNC 7 Report. JAMA. 2003; 289(19):2560-2572.
19. Ergina PL, Cook JA, Blazeby JM, et al. Challenges in evaluating surgical innovation. Lancet. 2009; 374(9695):1097-1104. 20. Rothwell PM. External validity of randomized controlled trials: “to whom do the results of this trial apply”? Lancet. 2005; 365(9453):82-93.
21. Kääriäinen I, Shipponen P, Siurala M. What fraction of hospital ulcer patients is eligible for prospective trials? Scand J Gastroenterol Suppl. 1991; 186:73-76.
22. Rothwell PM, Warlow CP; European Carotid Surgery Trialists’ Collaborative Group. Prediction of benefit from carotid endarterectomy in individual patients: a risk modeling study. Lancet. 1999;353(9170):2105-2110.
23. Cohen LJ. An Introduction to the Philosophy of Induction and Probability. New York, NY: Oxford University Press; 1989.
24. Nallamothu BK, Hayward RA, Bates ER. Beyond the randomized clinical trial: the role of effectiveness studies in evaluating cardiovascular therapies. Circulation. 2008; 118(12): 1294-1303.
25. Kravitz RL, Duan N, Braslow J. Evidence-based medicine, heterogeneity of treatment effects, and the trouble with averages. Milbank Q. 2004;82(4):661-687.
26. Awan Z, Seidah NG, MacFadyen JG, et al. Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem. 2012;58(1): 183-189.
27. Hayward RA, Krumholz H. Three reasons to abandon low density lipoprotein targets: an open letter to the adult treatment panel IV of the National Institutes of Health. Circ Cardiovasc Qual Outcomes. 2012; 5(1):2-5.
28. Cholesterol Treatment Trialists (CTT) Collaboration; Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a metaanalysis of data from 170,000 participants in 26 randomized trials. Lancet. 2010; 376(9753):1670-1681.
29. Lenzer J, Hoffman JR, Furberg CD, Ioannidis JPA. Ensuring the integrity of clinical practice guidelines: a tool for protecting patients. BMJ. In press.
30. Sniderman AD, Furberg CD. Why guideline-making requires reform. JAMA. 2009; 301(4):429-431.
31. Croskerry P. From mindless to mindful practiced cognitive bias and clinical decision making. N Engl J Med. 2013; 368(26): 2445-2448.
32. Kassirer JP, Wong JB, Kopelman RI. Learning Clinical Reasoning. 2nd ed. Baltimore, MD: Lippincott, Williams & Wilkins; 2010.
33. Thayer HS. Meaning and Action: A Critical History of Pragmatism. 2nd ed. Indianapolis, IN: Hackett Publishing Company; 1984:431.
34. Hill AB. Reflections on the controlled trial. Ann Rheum Dis. 1966; 25(2):107-113.